Compare GSK plc (GSK) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Trip.com Group Ltd — how do they compare? GSK plc trades at $52.72 (market cap $101.34B), while Trip.com Group Ltd trades at $43.82 (market cap $26.95B). The key difference: GSK plc is far larger — about 3.8× Trip.com Group Ltd's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TCOM | |
|---|---|---|
Market Cap | $101.34B | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $78.96 |
52-Week Low | $36.20 | $39.84 |
Enterprise Value | $121.95B | $19.65B |
Dividend Yield | 3.49% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Trip.com Group (TCOM) trades at $43.72, up 3.09% with strong profitability (net margin 48.65%) and attractive valuations (P/E 6.44). Recent Q1 2026 earnings missed estimates at $0.83 vs. $0.85 expected, though revenue grew 17% year-over-year. Technical indicators show mixed signals with bullish oscillators but overbought RSI levels, while support sits near $42.
Outlook remains positive with 67% analyst buy ratings and a $56.72 consensus target, but near-term risks include regulatory scrutiny in China and Q2 revenue guidance of 3%-8% growth lagging expectations. The stock offers value but faces execution and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
